BlackRock Inc. acquired a new position in Savara Inc. (NASDAQ: SVRA) in the undefined quarter, accor

Algert Global LLC boosted its position in Savara Inc. (NASDAQ: SVRA) by 53.7% during the undefined q

Deutsche Bank AG purchased a new position in Savara Inc. (NASDAQ: SVRA) during the second quarter, a

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory d

YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical compan

YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical compan

MOLBREEVI* BLA PDUFA Target Action Date Set for November 22, 2026MOLBREEVI MAAs Under Review by the

Savara (NASDAQ:SVRA) reported quarterly losses of $(0.16) per share which missed the analyst consens

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm

Savara Inc. (SVRA) is revisited, focusing on its APAP BLA filing progress. The article assesses SVRA

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm

SVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded

394,528 shares of Common Stock were sold for about $2.24 million on June 22, 2026, at a weighted ave

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical comp

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopha

Savara is transitioning from a single-asset biotech to a rare disease commercial infrastructure, wit

[url="]Savara Inc.[/url] (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company fo

Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm

[url="]Savara Inc.[/url] (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company fo

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm

[url="]Savara Inc.[/url] (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company fo

-- Data Were Presented in an Oral Presentation at the American Thoracic Society (ATS) International

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm

Savara (NASDAQ:SVRA) reported quarterly losses of $(0.15) per share which missed the analyst consens

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm

-- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (B

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare

Savara (NASDAQ:SVRA) reported quarterly losses of $(0.13) per share which met the analyst consensus

-- Day 74 Letter Received from the U.S. Food and Drug Administration (FDA) Indicated the Agency Has

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare

-- When Combined with Recently Announced $75M Royalty Financing, the Company Will Have Access to ~$1

PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for

HC Wainwright & Co. analyst Andrew S. Fein maintains Savara (NASDAQ:SVRA) with a Buy and rais

-- The BLA was Resubmitted with FUJIFILM Biotechnologies (Fujifilm) as the Drug Substance Manufactur

Wells Fargo analyst Benjamin Burnett maintains Savara (NASDAQ:SVRA) with a Overweight and raises

-- Once Granted, the Patent Will Provide Protection for MOLBREEVI in Europe Until March 2041 ---- Sa

"This patent covers our drug-device combination through March 2043," said Matt Pauls, J.D.,

Oppenheimer analyst Andreas Argyrides maintains Savara (NASDAQ:SVRA) with a Outperform and raises

Citizens analyst Jonathan Wolleben maintains Savara (NASDAQ:SVRA) with a Market Outperform and lo

Savara (NASDAQ:SVRA) reported quarterly losses of $(0.14) per share which missed the analyst consens

Savara intends to use the proceeds from the offering for general corporate purposes, which include t

Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare

– The Beneficial Clinical Effects of Molgramostim Were Similar in Patients with aPAP Regardless of D